Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
المؤلفون المشاركون
Tohyama, Osamu
Matsui, Junji
Kodama, Kotaro
Hata-Sugi, Naoko
Kimura, Takayuki
Okamoto, Kiyoshi
Minoshima, Yukinori
Iwata, Masao
Funahashi, Yasuhiro
المصدر
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-09-10
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer.
Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1–4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET.
We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice.
Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models.
Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells.
Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2.
Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells.
These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Tohyama, Osamu& Matsui, Junji& Kodama, Kotaro& Hata-Sugi, Naoko& Kimura, Takayuki& Okamoto, Kiyoshi…[et al.]. 2014. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models. Journal of Thyroid Research،Vol. 2014, no. 2014, pp.1-13.
https://search.emarefa.net/detail/BIM-1043266
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Tohyama, Osamu…[et al.]. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models. Journal of Thyroid Research No. 2014 (2014), pp.1-13.
https://search.emarefa.net/detail/BIM-1043266
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Tohyama, Osamu& Matsui, Junji& Kodama, Kotaro& Hata-Sugi, Naoko& Kimura, Takayuki& Okamoto, Kiyoshi…[et al.]. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models. Journal of Thyroid Research. 2014. Vol. 2014, no. 2014, pp.1-13.
https://search.emarefa.net/detail/BIM-1043266
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1043266
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر